Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0054 | 0.3888 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0054 | 0.3888 | 0.5 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0054 | 0.3888 | 0.5 |
Toxoplasma gondii | thioredoxin reductase | 0.0095 | 1 | 1 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0095 | 1 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0095 | 1 | 1 |
Loa Loa (eye worm) | histone deacetylase 7A | 0.004 | 0.1812 | 0.1812 |
Leishmania major | trypanothione reductase | 0.0095 | 1 | 1 |
Leishmania major | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Plasmodium falciparum | glutathione reductase | 0.0095 | 1 | 1 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0095 | 1 | 1 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0054 | 0.3888 | 0.5 |
Leishmania major | acetoin dehydrogenase e3 component-like protein | 0.0054 | 0.3888 | 0.2536 |
Treponema pallidum | NADH oxidase | 0.0054 | 0.3888 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0034 | 0.0923 | 0.0923 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0054 | 0.3888 | 0.5 |
Toxoplasma gondii | NADPH-glutathione reductase | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma brucei | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Plasmodium vivax | dihydrolipoyl dehydrogenase, apicoplast, putative | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma brucei | dihydrolipoamide dehydrogenase, point mutation | 0.0054 | 0.3888 | 0.2536 |
Plasmodium vivax | glutathione reductase, putative | 0.0095 | 1 | 1 |
Echinococcus multilocularis | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Loa Loa (eye worm) | histone deacetylase | 0.004 | 0.1812 | 0.1812 |
Brugia malayi | Histone deacetylase family protein | 0.004 | 0.1812 | 0.009 |
Loa Loa (eye worm) | glutathione reductase | 0.0095 | 1 | 1 |
Leishmania major | 2-oxoglutarate dehydrogenase, e3 component, lipoamidedehydrogenase-like protein | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma brucei | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Schistosoma mansoni | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0095 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0054 | 0.3888 | 0.5 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.5 |
Plasmodium falciparum | glutathione reductase | 0.0054 | 0.3888 | 0.2536 |
Brugia malayi | Histone deacetylase family protein | 0.004 | 0.1812 | 0.009 |
Plasmodium falciparum | thioredoxin reductase | 0.0054 | 0.3888 | 0.2536 |
Echinococcus granulosus | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0054 | 0.3888 | 0.5 |
Plasmodium falciparum | dihydrolipoyl dehydrogenase, mitochondrial | 0.0054 | 0.3888 | 0.2536 |
Plasmodium vivax | dihydrolipoyl dehydrogenase, mitochondrial, putative | 0.0054 | 0.3888 | 0.2536 |
Schistosoma mansoni | histone deacetylase hda2 | 0.0047 | 0.2735 | 0.1128 |
Echinococcus multilocularis | histone deacetylase 6 | 0.0047 | 0.2735 | 0.1128 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Toxoplasma gondii | pyruvate dehydrogenase complex subunit PDH-E3II | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma brucei | dihydrolipoyl dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0095 | 1 | 1 |
Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.0054 | 0.3888 | 0.2603 |
Trypanosoma brucei | trypanothione reductase | 0.0095 | 1 | 1 |
Trypanosoma cruzi | dihydrolipoyl dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma cruzi | dihydrolipoyl dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Brugia malayi | Thioredoxin reductase | 0.0095 | 1 | 1 |
Leishmania major | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0095 | 1 | 1 |
Echinococcus granulosus | histone deacetylase 6 | 0.0047 | 0.2735 | 0.1128 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0054 | 0.3888 | 0.2536 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0054 | 0.3888 | 0.5 |
Plasmodium falciparum | dihydrolipoyl dehydrogenase, apicoplast | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0054 | 0.3888 | 0.5 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0095 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 70 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.0015+0.06 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 73 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.003+0.015 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 74 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.0015+0.005 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 76 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.003+0.06 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 79 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.006+0.06 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 85 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.006+0.015 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 91 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.006+0.005 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 91 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.003+0.005 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 94 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.012+0.015 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 96 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.012+0.005 microM | ChEMBL. | 1901911 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.